Scilex holding companySCLX.US Overview
SCLX Overall Performance
SCLX AI Analysis & Strategy
SCLX Recent Performance
-0.44%
Scilex holding company
0.81%
Avg of Sector
-1.14%
S&P500
SCLX PowerScanner
SCLX Key Information
SCLX Valuation Metrics
SCLX Earnings Table
SCLX Profile
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.